Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by severely pruritic skin nodules.
Monoclonal antibody inhibiting signaling through oncostatin M receptor beta (OSMRβ).
Vixarelimab inhibits signaling of interleukin-31 (IL-31) and oncostatin M (OSM), 2 key cytokines implicated in inflammation, pruritus, and fibrosis.
We estimate that there are approximately 300,000 patients with PN in the United States.
Breakthrough Therapy designation granted by the US Food and Drug Administration (FDA) to vixarelimab for the treatment of pruritus associated with prurigo nodularis.
Studies link many pruritic and inflammatory diseases to both IL-31 and OSM via signaling through OSMRβ. By targeting both pathways simultaneously, vixarelimab may disrupt the pathologic cycle in patients afflicted by a variety of pruritic diseases.
We reported data from a randomized, double-blind, placebo-controlled Phase 2a clinical trial of vixarelimab in subjects with PN.
We reported data from an exploratory Phase 2 clinical trial of vixarelimab in diseases characterized by chronic pruritus. The trial was designed to identify chronic pruritic conditions where signaling through OSMRβ may be playing a role and to investigate the efficacy, safety, and tolerability of vixarelimab in reducing the moderate-tosevere pruritus experienced by these subjects.
We are not aware of any current therapies approved by the FDA for the treatment of PN.